S. A. Bolshakov

S. A. Bolshakov

Auto-generated profile, based on publicly available information

S. A. Bolshakov

Botkin Hospital

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2021 in Sechenov Medical Journal
Verified
Journal Article
Open access
PDF file
YIYu. V. Ilina
Yu. V. Ilina
TFT. A. Fedorova
T. A. Fedorova
STS. Y. Tazina
S. Y. Tazina
TST. I. Sotnikova
T. I. Sotnikova
NSN. A. Semenenko
N. A. Semenenko
CPChavdar Pavlov
Chavdar Pavlov
DRESS syndrome on the background of adding meropenem to carbamazepine therapy: a clinical case

20 September 2024 in Nephrology and Dialysis
Verified
Journal Article
Open access
PDF file
ESE. V. Shutov
E. V. Shutov
SBS. A. Bolshakov
S. A. Bolshakov
TMT. A. Makarova
T. A. Makarova
IFI. A. Fedoseeva
I. A. Fedoseeva
DTD. A. Teplyuk
D. A. Teplyuk
SSS. M. Sorokoletov
S. M. Sorokoletov
Recent technological advances have significantly enhanced our understanding of the role microbial communities play in the human body. The gut microbiota, one of the most diverse microbiomes, consists of over 35,000 bacterial species and 10 million genes, leading researchers to consider it as an additional organ. This whiles relatively stable within each individual highly influenced by exogenous and endogenous factors. Collectively, the gut microbiota functions as a "second genome", profoundly impacting the host’s metabolic pathways and regulating the body’s complex homeostatic balance.Research into the "microbe–host" interaction, both in health and disease, has garnered worldwide scientific. In chronic kidney disease (CKD), the gut microbiota undergoes significant changes, and growing evidences suggests that dysbiosis plays a crucial role in the progression of renal failure. Key pathological process, such as the production of gut-derived uremic toxins, decreased synthesis of short– chain fatty acids, altered intestinal pH, compromised intestinal barrier function, and heightened systemic inflammation, are all linked the intestinal microbiota. However, relationship between these changes and the pathogenesis and progression of kidney disease requires further investigation. Advances in microbiome research, including metagenomic and metatranscriptomic analyses, alongside proteomic, metabolomics, and immunomic studies, have greatly expanded our understanding of microbiomal community structure and functions. These technologies, coupled with mechanistic experiments in model systems, have deepened our knowledge of how the microbiome influences metabolism. Current research aims to explore the bidirectional relationship between the microbiota and the host, identifying potential interventions that could help restore a mutualistic relationship.

1 January 2024 in Nephrology and Dialysis
Verified
Journal Article
Closed access
GMGBUZ «S.P. Botkin City Clinical Hospital» Department of Health of the City of Moscow
GBUZ «S.P. Botkin City Clinical Hospital» Department of Health of the City of Moscow
DDD.D. Dolidze
D.D. Dolidze
FFFGBOU DPO Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation
FGBOU DPO Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation
ASA.V. Shabunin
A.V. Shabunin
GFGBUZ «S.P. Botkin City Clinical Hospital» Department of Health of the City of Moscow; FGBOU DPO Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation
GBUZ «S.P. Botkin City Clinical Hospital» Department of Health of the City of Moscow; FGBOU DPO Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation
SBS.A. Bolshakov
S.A. Bolshakov

10 December 2024 in Experimental and Clinical Gastroenterology
Verified
Journal Article
Open access
PDF file
DTD. A. Teplyuk
D. A. Teplyuk
OLO. N. Levina
O. N. Levina
CPCh. S. Pavlov
Ch. S. Pavlov
SSS. M. Sorokoletov
S. M. Sorokoletov
EPE. Yu. Pashkova
E. Yu. Pashkova
ESE. V. Shutov
E. V. Shutov
Nonalcoholic fatty liver disease (NAFLD) is most commonly a component of the metabolic syndrome with a global prevalence of 25% and the number of patients continues to increase. According to current projections, in the near future, NAFLD will become the most common indication for liver transplantation. The search for new risk factors for the development and progression of this disease is actively underway. The article considers the role of intestinal microbiota in proinflammatory processes, bile acid metabolism and liver lipogenesis. Attention is paid to the qualitative composition of the microbiome depending on the stage of NAFLD. Conclusions are made about heterogeneity of the research results in case of NAFLD and relatively stable microbiota in liver cirrhosis. Faecalibacterium prausnitzii and its role in the progression of NAFLD are considered separately. Probable reasons for the disagreement of the results of the studies are presented. In the part devoted to the treatment of NAFLD, the focus is on the ways of correction of intestinal dysbiosis, the influence of various microbiological preparations on lipogenesis and the process of inflammation in the liver. The optimal composition of probiotic preparations is discussed in detail. Their combination with prebiotics and isolated administration of inulin, fructooligosaccharide. Conclusions are drawn that in the future the assessment of intestinal microbiome will help to improve therapeutic approaches in the treatment of NAFLD patients.

1 January 2023 in Nephrology and Dialysis
Verified
Journal Article
Closed access
SMS.P. Botkin City Clinical Hospital Department of Health of the City of Moscow
S.P. Botkin City Clinical Hospital Department of Health of the City of Moscow
ASA.V. Shabunin
A.V. Shabunin
FFFGBOU DPO Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation
FGBOU DPO Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation
ESE.V. Shutov
E.V. Shutov
SFS.P. Botkin City Clinical Hospital Department of Health of the City of Moscow; FGBOU DPO Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation
S.P. Botkin City Clinical Hospital Department of Health of the City of Moscow; FGBOU DPO Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation
SBS.A. Bolshakov
S.A. Bolshakov

26 September 2022 in Nephrology
Verified
Journal Article
Closed access
SSShutov E.V. Shutov
Shutov E.V. Shutov
BBBolshakov S.A. Bolshakov
Bolshakov S.A. Bolshakov
KKKotlyarova G.V. Kotlyarova
Kotlyarova G.V. Kotlyarova
EEEmelyanova E.B. Emelyanova
Emelyanova E.B. Emelyanova
SSSorokoletov S.M. Sorokoletov
Sorokoletov S.M. Sorokoletov
MEMOSCOw RUSSIAN MedICAL ACAdemy Of CONTINUING PROfeSSIONAL EdUCATION
MOSCOw RUSSIAN MedICAL ACAdemy Of CONTINUING PROfeSSIONAL EdUCATION